These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 19776171

  • 1. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease.
    Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, Serra AL.
    Am J Physiol Renal Physiol; 2009 Dec; 297(6):F1597-605. PubMed ID: 19776171
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
    Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP.
    Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
    [Abstract] [Full Text] [Related]

  • 3. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
    Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, Serra AL.
    Kidney Blood Press Res; 2007 Mar; 30(4):253-9. PubMed ID: 17596700
    [Abstract] [Full Text] [Related]

  • 4. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C.
    Transplantation; 2007 Dec 15; 84(11):1492-9. PubMed ID: 18091526
    [Abstract] [Full Text] [Related]

  • 5. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP, Kistler AD, Serra AL.
    Transplant Proc; 2010 Nov 15; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [Abstract] [Full Text] [Related]

  • 6. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Hörl WH, Obermüller N, Arns W, Pavenstädt H, Gaedeke J, Büchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU.
    N Engl J Med; 2010 Aug 26; 363(9):830-40. PubMed ID: 20581392
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
    Berthier CC, Wahl PR, Le Hir M, Marti HP, Wagner U, Rehrauer H, Wüthrich RP, Serra AL.
    Nephrol Dial Transplant; 2008 Mar 26; 23(3):880-9. PubMed ID: 18042615
    [Abstract] [Full Text] [Related]

  • 8. Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction.
    Rovira J, Arellano EM, Carreras J, Campos B, Vodenik B, Bañón-Maneus E, Ramírez-Bajo MJ, Moya-Rull D, Solé-González A, Hernández A, Revuelta I, Quintana LF, Howat WJ, Campistol JM, Diekmann F.
    Transplantation; 2009 Sep 15; 88(5):646-52. PubMed ID: 19741461
    [Abstract] [Full Text] [Related]

  • 9. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
    Keller K, Daniel C, Schöcklmann H, Endlich KH, Kerjaschki D, Johnson RJ, Hugo C.
    Nephrol Dial Transplant; 2006 Oct 15; 21(10):2724-35. PubMed ID: 16861242
    [Abstract] [Full Text] [Related]

  • 10. Rapamycin prevents early steps of the development of diabetic nephropathy in rats.
    Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J.
    Am J Nephrol; 2007 Oct 15; 27(5):495-502. PubMed ID: 17671379
    [Abstract] [Full Text] [Related]

  • 11. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
    Sabbatini M, Russo L, Cappellaio F, Troncone G, Bellevicine C, De Falco V, Buonocore P, Riccio E, Bisesti V, Federico S, Pisani A.
    Am J Physiol Renal Physiol; 2014 May 15; 306(10):F1243-50. PubMed ID: 24647711
    [Abstract] [Full Text] [Related]

  • 12. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
    Tao Y, Kim J, Schrier RW, Edelstein CL.
    J Am Soc Nephrol; 2005 Jan 15; 16(1):46-51. PubMed ID: 15563559
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice.
    Sakaguchi M, Isono M, Isshiki K, Sugimoto T, Koya D, Kashiwagi A.
    Biochem Biophys Res Commun; 2006 Feb 03; 340(1):296-301. PubMed ID: 16364254
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.
    Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP.
    N Engl J Med; 2010 Aug 26; 363(9):820-9. PubMed ID: 20581391
    [Abstract] [Full Text] [Related]

  • 15. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
    Riegersperger M, Herkner H, Sunder-Plassmann G.
    Trials; 2015 Apr 23; 16():182. PubMed ID: 25899445
    [Abstract] [Full Text] [Related]

  • 16. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
    Dai B, Liu Y, Mei C, Fu L, Xiong X, Zhang Y, Shen X, Hua Z.
    Clin Sci (Lond); 2010 Jul 09; 119(8):323-33. PubMed ID: 20507283
    [Abstract] [Full Text] [Related]

  • 17. Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.
    Krämer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H.
    Am J Physiol Renal Physiol; 2008 Feb 09; 294(2):F440-9. PubMed ID: 18094032
    [Abstract] [Full Text] [Related]

  • 18. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov 09; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 19. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease.
    Edelstein CL.
    Clin J Am Soc Nephrol; 2008 Jul 09; 3(4):1219-26. PubMed ID: 18587045
    [Abstract] [Full Text] [Related]

  • 20. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.
    Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyó JM.
    J Am Soc Nephrol; 2006 May 09; 17(5):1395-404. PubMed ID: 16597691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.